Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Ardini

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Chirality|August 12, 2022
Stereoselective synthesis of 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as PIM kinase inhibitors inspired from marine alkaloidsFrancesco Casuscelli, Elena Ardini, Nilla Avanzi, et al.
Bioorganic & Medicinal Chemistry|October 22, 2013
Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinasesFrancesco Casuscelli, Elena Ardini, Nilla Avanzi, et al.
British Journal of Cancer|December 4, 2015
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancerAlessio Amatu, Alessio Somaschini, Giulio Cerea, et al.
Journal of the National Cancer Institute|November 14, 2015
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal CancerAndrea Sartore-Bianchi, Elena Ardini, Roberta Bosotti, et al.
Molecular Cancer Therapeutics|March 5, 2016
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Maria Menichincheri, Patrizia Banfi, et al.
Molecular Oncology|June 26, 2014
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibitionElena Ardini, Roberta Bosotti, Andrea Lombardi Borgia, et al.
Journal of Medicinal Chemistry|August 20, 2019
Correction to Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitorMaria Menichincheri, Elena Ardini, Paola Magnaghi, et al.
Journal of Medicinal Chemistry|March 23, 2016
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitorMaria Menichincheri, Elena Ardini, Paola Magnaghi, et al.
Cancer Discovery|February 11, 2017
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Chirality|August 12, 2022
Stereoselective synthesis of 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as PIM kinase inhibitors inspired from marine alkaloidsFrancesco Casuscelli, Elena Ardini, Nilla Avanzi, et al.
Bioorganic & Medicinal Chemistry|October 22, 2013
Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinasesFrancesco Casuscelli, Elena Ardini, Nilla Avanzi, et al.
British Journal of Cancer|December 4, 2015
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancerAlessio Amatu, Alessio Somaschini, Giulio Cerea, et al.
Journal of the National Cancer Institute|November 14, 2015
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal CancerAndrea Sartore-Bianchi, Elena Ardini, Roberta Bosotti, et al.
Molecular Cancer Therapeutics|March 5, 2016
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Maria Menichincheri, Patrizia Banfi, et al.
Molecular Oncology|June 26, 2014
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibitionElena Ardini, Roberta Bosotti, Andrea Lombardi Borgia, et al.
Journal of Medicinal Chemistry|August 20, 2019
Correction to Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitorMaria Menichincheri, Elena Ardini, Paola Magnaghi, et al.
Journal of Medicinal Chemistry|March 23, 2016
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitorMaria Menichincheri, Elena Ardini, Paola Magnaghi, et al.
Cancer Discovery|February 11, 2017
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, et al.
Pageof 2